inflection

Investing.com — The landscape of GLP-1 drugs, which are widely recognized for their efficacy in weight loss and diabetes management, is poised for a potential transformation in 2025, as per analysts at Barclays (LON:).  These drugs, exemplified by widely-known brands like Novo Nordisk’s Ozempic and Wegovy, are gaining prominence not…